Company Licenses Universal Donor Adult Stem Cell Product For CTE, Traumatic Brain Injury.
OCEANSIDE, Calif., Dec 10, 2018 -- Therapeutic Solutions International, Inc., (OTC: TSOI) has signed an agreement with Jadi Cell LLC to license the Jadi Cell universal donor adult stem cell (U.S. Patent No. 9,803,176 B2) for use in chronic traumatic encephalopathy (CTE) and traumatic brain injury (TBI).
The Jadi Cell product, comprising mesenchymal stem cells, produces higher levels of therapeutic factors compared to other stem cells.
The cells have demonstrated safety in animal models and pilot human trials.
The product is generated from umbilical cords, medical waste that is available cheaply in large quantities
Chronic traumatic encephalopathy (CTE) is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and is often found in football players.
The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression, depression, and dementia.
CTE is characterized by brain atrophy, reduced mass of frontal and temporal cortices, and medial temporal lobe.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Technology Licensing|
|Publication:||Stem Cell Research News|
|Date:||Dec 17, 2018|
|Previous Article:||The Source Of Stem Cells Points To Two Proteins.|
|Next Article:||Companies Expand Cell Therapy Collaboration To Pursue CRISPR/Cas9-based Genome Editing.|